Clinical Trial Update: Controlled Trial of 3,4-Diaminopyridine (3-4DAP) in Lambert-Eaton Myasthenic Syndrome (LEMS) [Phase 2]

View source ↗

Summary

Phase 2 trial of 3,4-Diaminopyridine (3-4DAP) in Lambert-Eaton Myasthenic Syndrome (LEMS) was terminated; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lambert-eaton Myasthenic Syndrome

Drugs mentioned

• 3,4-Diaminopyridine (3,4-diaminopyridine)

Snippet

Sponsor: Jeffrey A. Cohen, MD | Conditions: Muscle Weakness | Phase 2 | Status: TERMINATED | Results posted: 2019-05-21